Hemophilia A and B Recombinant Factor Replacement Therapy to 2024 is a new market research publication announced by Reportstack. Congenital Hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity.
Complete report available @ Hemophilia A and B Recombinant Factor Replacement Therapy to 2024
Argentina ranks fourth among pharmaceutical markets in Latin America. This growth will be primarily driven by overall pharmaceutical market growth and increasing use of recombinant prophylactic therapies by hemophilia patients. According to the primary research, the majority of Argentine hemophilia patients have access to factor replacement products through private insurance plans or through the national social security program. However, the national insurance program only covers on-demand treatment and plasma-derived concentrates.
Scope
- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Analysis of the impact of key events as well the drivers and restraints affecting Argentina Hemophilia A and B market.
- Analysis of the impact of key events as well the drivers and restraints affecting Argentina Hemophilia A and B market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B.
- Effectively plan your M&A and partnership strategies with the most promising sales potential
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B.
- Effectively plan your M&A and partnership strategies with the most promising sales potential
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
No comments:
Post a Comment